Royal Gold, Inc. 6,500,000 Shares Common Stock (par value $0.01 per share) Underwriting Agreement New York, New York April 7, 2009
Exhibit 1.1
EXECUTION
COPY
Royal Gold, Inc.
6,500,000 Shares
Common Stock
(par value $0.01 per share)
Common Stock
(par value $0.01 per share)
HSBC Securities (USA) Inc.
Xxxxxxx, Xxxxx & Co.
Scotia Capital (USA) Inc.
c/o HSBC Securities (USA) Inc.
000 Xxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Xxxxxxx, Xxxxx & Co.
Scotia Capital (USA) Inc.
c/o HSBC Securities (USA) Inc.
000 Xxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
as Representatives of the several Underwriters named in Schedule I hereto
Ladies and Gentlemen:
Royal Gold, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes
to sell to the several underwriters named in Schedule I to this Agreement (the “Underwriters”), for
whom you (the “Representatives”) are acting as representatives, 6,500,000 shares of common stock,
par value $0.01 per share (“Common Stock”), of the Company (said shares to be issued and sold by
the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to
grant to the Underwriters an option to purchase up to 975,000 additional shares of Common Stock to
cover over-allotments (the “Option Securities”; the Option Securities, together with the
Underwritten Securities, being hereinafter called the “Securities”). Any reference herein to the
Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Final Prospectus
shall be deemed to refer to and include the documents incorporated by reference therein pursuant to
Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the
Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus or the
Final Prospectus, as the case may be; and any reference herein to the terms “amend,” “amendment” or
“supplement” with respect to the Registration Statement, the Base Prospectus, any Preliminary
Prospectus or the Final Prospectus shall be deemed to refer to and include the filing of any
document under the Exchange Act after the Effective Date of the Registration Statement or the issue
date of the Base Prospectus, any Preliminary Prospectus or the Final Prospectus, as the case may
be, deemed to be incorporated therein by reference.
The Company has filed the Registration Statement, and the related multi-jurisdictional
disclosure system prospectus (the “Canadian MJDS Base Prospectus”), with securities regulatory
authorities (the “Canadian Regulators”) in each of the Canadian
provinces other than Quebec (the “Canadian Jurisdictions”), pursuant to and in accordance with
the Canadian Securities Administrators’ National Instrument 71-101 (“NI 71-101”), The
Multijurisdictional Disclosure System and applicable securities laws in the Canadian Jurisdictions
(collectively, the “MJDS Rule”), and has received a receipt for the Canadian MJDS Base Prospectus
from or on behalf of each of the Canadian Regulators.
Certain terms used herein are defined in Section 17 hereof.
1. Representations and Warranties.
The Company represents and warrants to, and agrees with, each Underwriter as set forth below
in this Section 1.
(i) The Company meets the requirements for use of Form S-3 under the Act and has
prepared and filed with the Commission an automatic shelf registration statement as defined
in Rule 405 (file number 333-156376) on Form S-3, including a related base prospectus, for
registration under the Act of the offering and sale of the Securities. Such Registration
Statement, including any amendments thereto filed prior to the Execution Time, became
effective upon filing. The Company may have filed with the Commission, as part of an
amendment to the Registration Statement or pursuant to Rule 424(b), one or more preliminary
prospectus supplements relating to the Securities, each of which has previously been
furnished to you. The Company will file with the Commission a final prospectus supplement
relating to the Securities in accordance with Rule 424(b). As filed, such final prospectus
supplement shall contain all information required by the Act and the rules thereunder, and,
except to the extent that the Representatives shall agree in writing to a modification,
shall be in all substantive respects in the form furnished to you prior to the Execution
Time or, to the extent not completed at the Execution Time, shall contain only such
specific additional information and other changes (beyond that contained in the Base
Prospectus and any Preliminary Prospectus) as the Company has advised you, prior to the
Execution Time, will be included or made therein. The Registration Statement, at the
Execution Time, meets the requirements set forth in Rule 415(a)(1)(x). The initial
Effective Date of the Registration Statement was not earlier than the date three years
before the Execution Time.
(ii) The Company meets the requirements for use of NI 71-101 and has, prior to the
Execution Time, prepared and filed a Canadian MJDS Base Prospectus and Preliminary Canadian
MJDS Supplement thereto in each of the Canadian Jurisdictions, along with other required
documents, and has received a receipt from or on behalf of each of the Canadian Regulators
for the Canadian MJDS Base Prospectus. Concurrently with the filing of a final prospectus
supplement with the Commission as described in Section (1)(i) above, the Company will file
with the Canadian Regulators a final Canadian MJDS supplement relating to the Securities
and substantially in the form of the final prospectus supplement described in Section
(1)(i) above with whatever additional items are required pursuant to the MJDS Rule.
2
(iii) On the Effective Date, the Registration Statement did, and when the Final
Prospectus is first filed in accordance with Rule 424(b) and on the Closing Date (as
defined herein) and on any date on which Option Securities are purchased, if such date is
not the Closing Date (a “settlement date”), the Final Prospectus (and any supplement
thereto) will, comply in all material respects with the applicable requirements of the Act
and the Exchange Act and the respective rules thereunder; on the date of filing with the
Canadian Regulators, the Canadian MJDS Base Prospectus did, and when the Final Canadian
MJDS Supplement is first filed in accordance with the MJDS Rule and on the Closing Date and
any settlement date, the Final Canadian MJDS Supplement (and any supplement thereto) will,
comply in all material respects with the applicable requirements of the MJDS Rule; on the
date of filing with the Canadian Regulators and at the Execution Time, the Canadian MJDS
Base Prospectus did not and will not contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary in order to make
the statements therein not misleading; on the Effective Date and at the Execution Time, the
Registration Statement did not and will not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in order to
make the statements therein not misleading; and on the date of any filing pursuant to Rule
424(b) or NI 71-101 and on the Closing Date and any settlement date, the Final Prospectus
and the Final Canadian MJDS Supplement (in each case, together with any supplement thereto)
will not include any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; provided, however, that the Company
makes no representations or warranties as to the information contained in or omitted from
the Registration Statement or the Final Prospectus (or any supplement thereto) or the
Canadian MJDS Base Prospectus or the Final Canadian MJDS Supplement (or any supplement
thereto) in reliance upon and in conformity with information furnished in writing to the
Company by or on behalf of any Underwriter through the Representatives specifically for
inclusion in the Registration Statement or the Final Prospectus (or any supplement thereto)
or the Canadian MJDS Base Prospectus or the Final Canadian MJDS Supplement (or any
supplement thereto), as the case may be, it being understood and agreed that the only such
information furnished by or on behalf of any Underwriter consists of the information
described as such in the letter agreement between you and the Representatives dated the
date hereof.
(iv) As of the Applicable Time, the Disclosure Package and each electronic roadshow
that is a written communication when taken together as a whole with the Disclosure Package
does not contain any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The preceding sentence does not apply to statements
in or omissions from the Disclosure Package based upon and in conformity with written
information furnished to the Company by any Underwriter through the Representatives
specifically for use therein, it being understood and agreed that
3
the only such information furnished by or on behalf of any Underwriter consists of the
information described as such in the letter agreement between you and the Representatives
dated the date hereof.
(v) (1) At the time of filing the Registration Statement, (2) at the time of the most
recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Act
(whether such amendment was by post-effective amendment, incorporated report filed pursuant
to Sections 13 or 15(d) of the Exchange Act or form of prospectus), (3) at the time the
Company or any person acting on its behalf (within the meaning, for this clause only, of
Rule 163(c)) made any offer relating to the Securities in reliance on the exemption in Rule
163, and (4) at the Applicable Time (with such date being used as the determination date
for purposes of this clause (4)), the Company was or is (as the case may be) a “well-known
seasoned issuer” as defined in Rule 405. The Company agrees to pay the fees required by
the Commission relating to the Securities within the time required by Rule 456(b)(1)
without regard to the proviso therein and otherwise in accordance with Rules 456(b) and
457(r).
(vi) Each Issuer Free Writing Prospectus does not include any information that
conflicts with the information contained in the Registration Statement, including any
document incorporated therein by reference and any prospectus supplement deemed to be a
part thereof that has not been superseded or modified. The foregoing sentence does not
apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and
in conformity with written information furnished to the Company by any Underwriter through
the Representatives specifically for use therein, it being understood and agreed that the
only such information furnished by or on behalf of any Underwriter consists of the
information described as such in the letter agreement between you and the Representatives
dated the date hereof.
(vii) The Company is not the subject of a cease trade order, or management cease trade
order, issued by the Canadian Regulators, or any of them, and the Company is, to the best
of its knowledge, not aware of any such order being contemplated or threatened by the
Canadian Regulators, or any of them.
(viii) The Company is a reporting issuer, or the equivalent thereof, under the
securities laws of each of the Canadian Jurisdictions (the “Canadian Securities Laws”), is
not in default of any requirement of the Canadian Securities Laws, and the Company is not
included on a list of defaulting reporting issuers maintained by any of the Canadian
Regulators that maintain such lists.
(ix) All disclosure and filings on the public record and fees required to be made and
paid by the Company and its subsidiaries pursuant to the Canadian Securities Laws have been
made and paid, and the Company has not filed any confidential material change reports.
4
(x) Each of the Company and its subsidiaries has been duly incorporated and is validly
existing as a corporation in good standing under the laws of the jurisdiction in which it
is chartered or organized with full corporate power and authority to own or lease, as the
case may be, and to operate its properties and conduct its business as described in the
Disclosure Package, the Final Prospectus and the Final Canadian MJDS Supplement, and is
duly qualified to do business as a foreign corporation and is in good standing under the
laws of each jurisdiction which requires such qualification and in which the failure to
qualify would have a Material Adverse Effect.
(xi) All the outstanding shares of capital stock of each subsidiary of the Company
have been duly and validly authorized and issued and are fully paid and nonassessable, and
all outstanding shares of capital stock of the Company’s subsidiaries are owned by the
Company, either directly or through wholly owned subsidiaries, free and clear of any
security interests, claims, liens or encumbrances, other than the capital stock of High
Desert Mineral Resources, Inc. (“High Desert”) and of RG Mexico, Inc., which has been
pledged pursuant to that certain Third Amended and Restated Credit Agreement, dated as of
October 31, 2008, among the Company, High Desert, the guarantors from time to time party
thereto, HSBC Bank USA, National Association, HSBC Securities (USA) Inc. and The Bank of
Nova Scotia.
(xii) The Company’s authorized equity capitalization is as set forth in the Disclosure
Package, the Final Prospectus and the Final Canadian MJDS Supplement. The share capital of
the Company conforms in all material respects to the description thereof contained in the
Disclosure Package, the Final Prospectus and the Final Canadian MJDS Supplement. The
outstanding shares of Common Stock have been duly and validly authorized and issued and are
fully paid and nonassessable. The Securities being sold hereunder by the Company have been
duly and validly authorized, and, when issued and delivered to and paid for by the
Underwriters pursuant to this Agreement, will be fully paid and nonassessable. The
certificates for the Securities are in valid and sufficient form. The holders of
outstanding shares of capital stock of the Company are not entitled to preemptive or other
rights to subscribe for the Securities; and except as set forth in the Final Prospectus and
the Final Canadian MJDS Supplement, no options, warrants or other rights to purchase,
agreements or other obligations to issue, or rights to convert any obligations into or
exchange any securities for, shares of capital stock of or ownership interests in the
Company are outstanding as of the date of the information set forth in the Final Prospectus
and the Final Canadian MJDS Supplement in respect of the capitalization of the Company.
(xiii) Neither the Company nor any of its subsidiaries has sustained since the date of
the latest audited financial statements included or incorporated by reference in the
Disclosure Package, the Final Prospectus and the Final Canadian MJDS Supplement any
material loss or interference with its business from fire, explosion, flood or other
calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, otherwise than
5
as set forth or contemplated in the Disclosure Package, the Final Prospectus and the
Final Canadian MJDS Supplement; and, since the respective dates as of which information is
given in the Registration Statement, the Canadian MJDS Base Prospectus, the Disclosure
Package, the Final Prospectus and the Final Canadian MJDS Supplement, there has not been
any change in the capital stock or long-term debt of the Company or any of its subsidiaries
or any material adverse change, or any development involving a prospective material adverse
change, in or affecting the general affairs, management, financial position, stockholders’
equity or results of operations of the Company and its subsidiaries, except as set forth in
the Final Prospectus and the Final Canadian MJDS Supplement.
(xiv) There is no franchise, contract or other document of a character required to be
described in the Registration Statement, the Disclosure Package or the Final Prospectus, or
to be filed as an exhibit thereto, which is not described or filed as required; and the
statements in the Final Prospectus under the headings “Tax Considerations,” “Risk Factors
— Risks Related to Our Business — Anticipated federal legislation could decrease our
royalty revenues” and “— The mining industry is subject to significant environmental
risks,” and “Material United States Federal Income Tax Considerations for Non-U.S. Holders”
and in the Base Prospectus under the heading “Description of Capital Stock,” insofar as
such statements summarize legal matters, agreements, documents or proceedings discussed
therein, are accurate and fair summaries of such legal matters, agreements, documents or
proceedings.
(xv) The Company is not and, after giving effect to the offering and sale of the
Securities and the application of the proceeds thereof as described in the Final
Prospectus, will not be an “investment company” as defined in the Investment Company Act of
1940, as amended.
(xvi) No consent, approval, authorization, filing with or order of any court or
governmental agency or body is required in connection with the transactions contemplated
herein, except (1) such as have been obtained under the Act, (2) such as may be required by
the Financial Industry Regulatory Authority, the NASDAQ Global Select Market and the
Toronto Stock Exchange, (3) such as may be required under the blue sky laws of any
jurisdiction in connection with the purchase and distribution of the Securities by the
Underwriters in the manner contemplated herein and in the Final Prospectus and (4) such as
may be required with the Canadian Regulator in each of the Canadian Jurisdictions.
(xvii) None of the issue and sale of the Securities, the execution and delivery by the
Company of this Agreement and the consummation of any other of the transactions herein
contemplated or the fulfillment of the terms hereof will conflict with, result in a breach
or violation of, or result in the imposition of any lien, charge or encumbrance upon any
property or assets of the Company or any of its subsidiaries pursuant to (1) the
organizational documents of the Company or any of its subsidiaries, (2) the terms of any
indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or
other agreement, obligation, condition, covenant or instrument to which the Company or any
of its subsidiaries
6
is a party or bound or to which its or their property is subject, (3) any statute,
law, rule, or regulation, or (4) any judgment, writ, injunction, ruling, order or decree of
any court, regulatory body, administrative agency, governmental body, arbitrator or other
authority having jurisdiction over the Company or any of its subsidiaries or any of its or
their properties.
(xviii) The consolidated historical financial statements of the Company and its
subsidiaries included or incorporated by reference in the Disclosure Package, the Final
Prospectus, the Registration Statement, the Final Canadian MJDS Supplement and the Canadian
MJDS Base Prospectus present fairly in all material respects the consolidated financial
condition, results of operations and cash flows of the Company and its subsidiaries as of
the dates and for the periods indicated, comply as to form with the applicable accounting
requirements of the Act and the Exchange Act and the MJDS Rule (as modified by the
exemptive relief, received by or on behalf of the Canadian Regulators, from the GAAP
reconciliation requirement in NI 71-101 relating to equity offerings) and have been
prepared in conformity with United States generally accepted accounting principles applied
on a consistent basis throughout the periods involved (except as otherwise noted therein).
The selected consolidated financial data set forth under the caption “Prospectus Supplement
Summary — Summary of Consolidated Financial Data” in the Final Prospectus, the Final
Canadian MJDS Supplement and the Disclosure Package fairly present, on the basis stated in
the Final Prospectus, the Final Canadian MJDS Supplement and the Disclosure Package, the
information included therein.
(xix) No action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries or its
or their property is pending or, to the knowledge of the Company, threatened that could
reasonably be expected to have a Material Adverse Effect, except as set forth in the Final
Prospectus and the Final Canadian MJDS Supplement (in each case, exclusive of any
supplements thereto).
(xx) Each of the Company and each of its Significant Subsidiaries owns or leases all
such properties as are necessary to the conduct of its operations as presently conducted;
the Company and its Significant Subsidiaries have good and marketable title to all real
property owned by them in fee simple, defensible title to all unpatented mining claims
owned by them (subject to the paramount title of the United States), and good and
marketable title to all personal property owned by them, in each case free and clear of all
liens, encumbrances and defects except as set forth in the Final Prospectus and the Final
Canadian MJDS Supplement or such as do not materially affect the value of such property and
do not interfere with the use made and proposed to be made of such property by the Company
and its Significant Subsidiaries; and any real property and buildings held under lease by
the Company and its Significant Subsidiaries are held by them under valid, subsisting and
enforceable leases with such exceptions as are not material and do not interfere with the
use made and proposed to be made of such property and buildings by the Company and its
Significant Subsidiaries.
7
(xxi) Neither the Company nor any subsidiary of the Company is in violation or default
of (1) any provision of its organizational documents, (2) the terms of any indenture,
contract, lease, mortgage, deed of trust, note agreement, loan agreement or other
agreement, obligation, condition, covenant or instrument to which it is a party or bound or
to which its property is subject, or (3) any statute, law, rule, regulation, judgment,
order or decree of any court, regulatory body, administrative agency, governmental body,
arbitrator or other authority having jurisdiction over the Company or such subsidiary or
any of its properties, as applicable, any of which defaults or violations described in
clauses (2) through (3) will have, or after any required notice and passage of any
applicable grace period, would have, a Material Adverse Effect.
(xxii) PricewaterhouseCoopers LLP, who have certified certain financial statements of
the Company and its consolidated subsidiaries and delivered their report with respect to
the audited consolidated financial statements and schedules included or incorporated by
reference in the Disclosure Package, the Final Prospectus and the Final Canadian MJDS
Supplement, is an independent registered public accounting firm with respect to the Company
within the meaning of the Act and the Exchange Act and the applicable published rules and
regulations thereunder.
(xxiii) The Company has filed all foreign, federal, state and local tax returns that
are required to be filed or has requested extensions thereof (except in any case in which
the failure so to file would not have a Material Adverse Effect), and has paid all taxes
required to be paid by it and any other assessment, fine or penalty levied against it, to
the extent that any of the foregoing is due and payable, except for any such assessment,
fine or penalty that is currently being contested in good faith or as would not have a
Material Adverse Effect.
(xxiv) No labor problem or dispute with the employees of the Company or any of its
Significant Subsidiaries exists or is threatened or imminent, and the Company is not aware
of any existing or imminent labor disturbance by the employees of any of its or its
Significant Subsidiaries’ principal suppliers, contractors or customers, that could have a
Material Adverse Effect.
(xxv) The Company and each of its Significant Subsidiaries are insured by insurers of
recognized financial responsibility against such losses and risks and in such amounts as
are prudent and customary in the businesses in which they are engaged; all policies of
insurance and fidelity or surety bonds insuring the Company or any of its Significant
Subsidiaries or their respective businesses, assets, employees, officers and directors are
in full force and effect; the Company and its Significant Subsidiaries are in compliance
with the terms of such policies and instruments in all material respects; there are no
claims by the Company or any of its subsidiaries under any such policy or instrument as to
which any insurance company is denying liability or defending under a reservation of rights
clause; neither the Company nor any such Significant Subsidiary has been refused any
insurance coverage sought or applied for; and neither the Company nor any such Significant
Subsidiary has any reason to believe that it will not be able to
8
renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business at a
cost that would not have a Material Adverse Effect.
(xxvi) No subsidiary of the Company is currently prohibited, directly or indirectly,
from paying any dividends to the Company, from making any other distribution on such
subsidiary’s capital stock, from repaying to the Company any loans or advances to such
subsidiary from the Company or from transferring any of such subsidiary’s property or
assets to the Company or any other subsidiary of the Company.
(xxvii) The Company and its subsidiaries possess all licenses, concessions,
certificates, permits and other authorizations issued by the appropriate federal, state or
foreign regulatory authorities necessary to conduct their respective businesses
(“Permits”); the Company and its subsidiaries have fulfilled and performed in all material
respects all of their respective obligations with respect to such Permits, and neither the
Company nor any such subsidiary has received any notice of proceedings relating to the
revocation or modification of any such Permit which, singly or in the aggregate, if the
subject of an unfavorable decision, ruling or finding, would have a Material Adverse
Effect, except as set forth in the Final Prospectus and the Final Canadian MJDS Supplement
(in each case, exclusive of any supplement thereto).
(xxviii) The Company and each of its subsidiaries maintains and will maintain a system
of internal accounting controls sufficient to provide reasonable assurance that (1)
transactions are executed in accordance with management’s general or specific
authorizations; (2) transactions are recorded as necessary to permit preparation of
financial statements in conformity with United States generally accepted accounting
principles and to maintain asset accountability; (3) access to assets is permitted only in
accordance with management’s general or specific authorization; and (4) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. The Company and its
subsidiaries’ internal controls over financial reporting are effective, and the Company and
its subsidiaries are not aware of any material weakness in their internal controls over
financial reporting. The Company maintains and will maintain disclosure controls and
procedures (as defined as Rule 13a-15 and 15d-15(e) of the Exchange Act); such disclosure
controls and procedures are effective.
(xxix) The Company has not taken, directly or indirectly, any action designed to or
that would constitute or that might reasonably be expected to cause or result in, under the
Exchange Act or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Securities.
(xxx) The Company and its subsidiaries (1) have been and are in compliance with any
and all applicable foreign, federal, state and local laws and regulations relating to the
protection of human health and safety, the environment,
9
hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental
Laws”), (2) have received and have been and are in compliance with all permits, licenses or
other approvals required of them under applicable Environmental Laws to conduct their
respective businesses and (3) have not received notice of any actual or potential liability
under any Environmental Law, except where such non-compliance with Environmental Laws,
failure to receive required permits, licenses or other approvals, or liability would not,
individually or in the aggregate, have a Material Adverse Effect, except as set forth in
the Final Prospectus and the Final Canadian MJDS Supplement (in each case, exclusive of any
supplement thereto). Except as set forth in the Disclosure Package, the Final Prospectus
(exclusive of any supplement thereto) and the Final Canadian MJDS Supplement (exclusive of
any supplement thereto), neither the Company nor any of its subsidiaries has been named as
a “potentially responsible party” under the Comprehensive Environmental Response,
Compensation, and Liability Act of 1980, as amended, or any similar state Environmental
Laws, or is subject to any pending or threatened proceeding in which a governmental entity
is a party except for such proceedings that would involve monetary sanctions of less than
$100,000.
(xxxi) In the ordinary course of its business, the Company periodically reviews the
effect of Environmental Laws on the business, operations and properties of the Company and
its subsidiaries, in the course of which it identifies and evaluates associated costs and
liabilities of the Company and its subsidiaries. On the basis of such review, the Company
has reasonably concluded that such associated costs and liabilities would not, singly or in
the aggregate, have a Material Adverse Effect, except as set forth in the Final Prospectus
and the Final Canadian MJDS Supplement (in each case, exclusive of any supplement thereto).
(xxxii) The minimum funding standard under Section 302 of the Employee Retirement
Income Security Act of 1974, as amended, and the regulations and published interpretations
thereunder (“ERISA”), has been satisfied by each “pension plan” (as defined in Section 3(2)
of ERISA) which has been established or maintained by the Company and/or one or more of its
subsidiaries, and the trust forming part of each such plan which is intended to be
qualified under Section 401 of the Internal Revenue Code of 1986, as amended, is so
qualified except in any case in which the failure to maintain such minimum funding standard
or such qualification would not have a Material Adverse Effect; each of the Company and its
subsidiaries has fulfilled its obligations, if any, under Section 515 of ERISA; neither the
Company nor any of its subsidiaries maintains or is required to contribute to a “welfare
plan” (as defined in Section 3(1) of ERISA) which provides for retiree or other
post-employment welfare benefits or insurance coverage as to which the Company has not
reserved its right to amend or terminate the plan in its discretion (other than
“continuation coverage” (as defined in Section 602 of ERISA)); each pension plan and
welfare plan established or maintained by the Company and/or one or more of its
subsidiaries is in compliance in all material respects with the currently applicable
provisions of ERISA; and neither the Company nor any of its subsidiaries has incurred or
10
could reasonably be expected to incur any withdrawal liability under Section 4201 of
ERISA, any liability under Section 4062, 4063 or 4064 of ERISA, or any other liability
under Title IV of ERISA.
(xxxiii) There is and has been no failure on the part of the Company and any of the
Company’s directors or officers, in their capacities as such, to comply with any provision
of the Sarbanes Oxley Act of 2002 and the rules and regulations promulgated in connection
therewith (the “Sarbanes Oxley Act”), including Section 402 related to loans and Sections
302 and 906 related to certifications.
(xxxiv) Neither the Company nor any of its Significant Subsidiaries nor, to the
knowledge of the Company, any director, officer, agent, employee or affiliate of the
Company or any of its Significant Subsidiaries is aware of or has taken any action,
directly or indirectly, that would result in a violation by such persons of the Foreign
Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the
“FCPA”), including, without limitation, making use of the mails or any means or
instrumentality of interstate commerce corruptly in furtherance of an offer, payment,
promise to pay or authorization of the payment of any money, or other property, gift,
promise to give, or authorization of the giving of anything of value to any “foreign
official” (as such term is defined in the FCPA) or any foreign political party or official
thereof or any candidate for foreign political office, in contravention of the FCPA, and
the Company and its Significant Subsidiaries have conducted their businesses in compliance
with the FCPA and have instituted and maintain policies and procedures designed to ensure,
and which are reasonably expected to continue to ensure, continued compliance therewith.
(xxxv) The operations of the Company and its Significant Subsidiaries are and have
been conducted at all times in compliance in all material respects with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the
rules and regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any governmental agency (collectively, the
“Money Laundering Laws”), and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of
its Significant Subsidiaries with respect to the Money Laundering Laws is pending or, to
the knowledge of the Company, threatened.
(xxxvi) Neither the Company nor any of its Significant Subsidiaries nor, to the
knowledge of the Company, any director, officer, agent or employee of the Company or any of
its Significant Subsidiaries is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company
will not directly or indirectly use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity, for
11
the purpose of financing the activities of any person currently subject to any U.S.
sanctions administered by OFAC.
(xxxvii) The Company and its subsidiaries own, possess, license or have other rights
to use, on reasonable terms, all patents, patent applications, trade and service marks,
trade and service xxxx registrations, trade names, copyrights, licenses, inventions, trade
secrets, technology, know-how and other intellectual property (collectively, the
“Intellectual Property”) necessary for the conduct of the Company’s business as now
conducted or as proposed in the Disclosure Package and the Final Prospectus to be
conducted. (1) To the Company’s knowledge, there are no rights of third parties to any
such Intellectual Property; (2) to the Company’s knowledge, there is no material
infringement by third parties of any such Intellectual Property; (3) there is no pending
or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others
challenging the Company’s rights in or to any such Intellectual Property, and the Company
is unaware of any facts which would form a reasonable basis for any such claim; (4) there
is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim
by others challenging the validity or scope of any such Intellectual Property, and the
Company is unaware of any facts which would form a reasonable basis for any such claim; (5)
there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or
claim by others that the Company infringes or otherwise violates any patent, trademark,
copyright, trade secret or other proprietary rights of others, and the Company is unaware
of any other fact which would form a reasonable basis for any such claim; (6) to the
Company’s knowledge, there is no U.S. or foreign patent or published U.S. patent
application which contains claims that dominate or may dominate any Intellectual Property
described in the Disclosure Package, the Final Prospectus or the Final Canadian MJDS
Supplement as being owned by or licensed to the Company or that interferes with the issued
or pending claims of any such Intellectual Property; and (7) there is no prior art of which
the Company is aware that may render any U.S. patent held by the Company invalid or any
U.S. patent application held by the Company unpatentable which has not been disclosed to
the U.S. Patent and Trademark Office.
(xxxviii) Except as disclosed in the Registration Statement, the Canadian MJDS Base
Prospectus, the Disclosure Package, the Final Prospectus and the Final Canadian MJDS
Supplement, the Company (1) does not have any material lending or other relationship with
any bank or lending affiliate of any Underwriter and (2) does not intend to use any of the
proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to
any affiliate of any Underwriter.
(xxxix) The offering is of a class of securities for which a bona fide independent
market exists as of the date of the filing of the Registration Statement and as of the
Effective Date.
(xl) Nothing has come to the attention of the Company that has caused the Company to
believe that the material reserve-related data included or incorporated by reference in the
Registration Statement, the Disclosure Package,
12
the Final Prospectus, the Canadian MJDS Base Prospectus and the Final Canadian MJDS
Supplement is not reliable in all material respects (it being understood that the Company
does not independently verify the reliability of such reserve-related data).
(xli) The Company has full right, power and authority to execute and deliver this
Agreement and to perform its obligations hereunder; and all corporate action required to be
taken for the due and proper authorization, execution and delivery by it of this Agreement
and the consummation by it of the transactions contemplated hereby has been duly and
validly taken.
(xlii) The Master Agreement, dated April 3, 2009 (the “Master Agreement”), between the
Company and Compañiá Xxxxxx Xxxxxx de Andacollo (“CDA”) has been duly authorized, executed
and delivered by the Company. To the knowledge of the Company, there has not been any
“Material Adverse Effect” (as such term is defined in the Master Agreement) that would give
any party thereto the right to terminate the Master Agreement.
Any certificate signed by any officer of the Company and delivered to the Representatives or
counsel for the Underwriters in connection with the offering of the Securities shall be deemed to
be a representation and warranty by the Company, as to matters covered thereby, to each
Underwriter.
2. Purchase and Sale. (a) Subject to the terms and conditions and in reliance upon
the representations and warranties herein set forth, the Company agrees to sell to each
Underwriter, and each Underwriter agrees, severally and not jointly, to purchase from the Company,
at the purchase price of $36.29 per share, the amount of the Underwritten Securities set forth
opposite such Underwriter’s name in Schedule I to this Agreement.
(b) Subject to the terms and conditions and in reliance upon the representations and
warranties herein set forth, the Company hereby grants an option to the several Underwriters to
purchase, severally and not jointly, up to 975,000 Option Securities at the same purchase price per
share as the Underwriters shall pay for the Underwritten Securities. Such option may be exercised
in whole or in part to cover over-allotments at any time on or before the 30th day after the date
of the Final Prospectus upon written or telegraphic notice by the Representatives to the Company
setting forth the number of shares of the Option Securities as to which the several Underwriters
are exercising the option and the settlement date. The number of Option Securities to be purchased
by each Underwriter shall be the same percentage of the total number of shares of the Option
Securities to be purchased by the several Underwriters as such Underwriter is purchasing of the
Underwritten Securities, subject to such adjustments as you in your absolute discretion shall make
to eliminate any fractional shares.
3. Delivery and Payment. Delivery of and payment for the Underwritten Securities and
the Option Securities (if the option provided for in Section 2(b) hereof shall have been exercised
on or before the third Business Day prior to the Closing Date) shall be made at 10:00 AM, New York
City time, on April 14, 2009, or at such time on
13
such later date not more than three Business Days after the foregoing date as the
Representatives shall designate, which date and time may be postponed by agreement between the
Representatives and the Company or as provided in Section 9 hereof (such date and time of delivery
and payment for the Securities being herein called the “Closing Date”). Delivery of the Securities
shall be made to the Representatives for the respective accounts of the several Underwriters
against payment by the several Underwriters through the Representatives of the respective aggregate
purchase prices of the Securities being sold by the Company to or upon the order of the Company by
wire transfer payable in same-day funds to the account specified by the Company. Delivery of the
Underwritten Securities and the Option Securities shall be made through the facilities of The
Depository Trust Company unless the Representatives shall otherwise instruct.
If the option provided for in Section 2(b) hereof is exercised after the third Business Day
prior to the Closing Date, the Company will deliver the Option Securities (at the expense of the
Company) to the Representatives, at 000 Xxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx, xx the date specified by
the Representatives (which shall be within three Business Days after exercise of such option) for
the respective accounts of the several Underwriters, against payment by the several Underwriters
through the Representatives of the purchase price thereof to or upon the order of the Company by
wire transfer payable in same-day funds to the account specified by the Company. If settlement for
the Option Securities occurs after the Closing Date, the Company will deliver to the
Representatives on the settlement date for the Option Securities, and the obligation of the
Underwriters to purchase the Option Securities shall be conditioned upon receipt of, supplemental
opinions, certificates and letters confirming as of such date the opinions, certificates and
letters delivered on the Closing Date pursuant to Section 6 hereof.
4. Offering by Underwriters. It is understood that the several Underwriters propose
to offer the Securities for sale to the public as set forth in the Final Prospectus and the Final
Canadian MJDS Supplement and in accordance with the selling restrictions set forth in Exhibit D
hereto.
5. Agreements.
The Company agrees with the several Underwriters that:
(i) Prior to the termination of the offering of the Securities, the Company will not
file any amendment to the Registration Statement or supplement (including the Final
Prospectus or any Preliminary Prospectus) to the Base Prospectus or the Canadian MJDS Base
Prospectus unless the Company has furnished you a copy for your review prior to filing and
will not file any such proposed amendment or supplement to which you reasonably object,
unless required by the Act or the Exchange Act or the MJDS Rule, as applicable. Subject to
the foregoing sentence, the Company will cause the Final Prospectus and the Final Canadian
MJDS Supplement, properly completed, and any supplement thereto to be filed in a form
approved by the Representatives with the Commission or the Canadian Regulators, as the case
may be, pursuant to the applicable paragraph of Rule 424(b) or the MJDS Rule within the
time period prescribed and will provide evidence satisfactory to the Representatives of
such
14
timely filing. The Company will promptly advise the Representatives (1) when the
Final Prospectus and the Final Canadian MJDS Supplement, and any supplement thereto, shall
have been filed (if required) with the Commission pursuant to Rule 424(b), or the Canadian
Regulators, as the case may be, (2) when, prior to termination of the offering of the
Securities, any amendment to the Registration Statement shall have been filed or become
effective, (3) of any request by the Commission or its staff for any amendment of the
Registration Statement, or for any supplement to the Final Prospectus or for any additional
information, (4) of the issuance by the Commission of any stop order suspending the
effectiveness of the Registration Statement or of any notice objecting to its use or the
institution or threatening of any proceeding for that purpose and (5) of the receipt by the
Company of any notification with respect to the suspension of the qualification of the
Securities for sale in any jurisdiction or the institution or threatening of any proceeding
for such purpose. The Company will use its best efforts to prevent the issuance of any
such stop order or the occurrence of any such suspension or objection to the use of the
Registration Statement and, upon such issuance, occurrence or notice of objection, to
obtain as soon as possible the withdrawal of such stop order or relief from such occurrence
or objection, including, if necessary, by filing an amendment to the Registration Statement
or a new registration statement and using its best efforts to have such amendment or new
registration statement declared effective as soon as practicable.
(ii) If, at any time prior to the filing of the Final Prospectus pursuant to Rule
424(b) or the filing of the Final Canadian MJDS Supplement pursuant to the MJDS Rule, any
event occurs as a result of which the Disclosure Package, as of the Applicable Time, would
include any untrue statement of a material fact or omit to state any material fact
necessary to make the statements therein in the light of the circumstances under which they
were made or the circumstances then prevailing not misleading, the Company will (1) notify
promptly the Representatives so that any use of the Disclosure Package may cease until it
is amended or supplemented, (2) amend or supplement the Disclosure Package to correct such
statement or omission, and (3) supply any amendment or supplement to you in such quantities
as you may reasonably request.
(iii) If, at any time when a prospectus relating to the Securities is required to be
delivered under the Act (including in circumstances where such requirement may be satisfied
pursuant to Rule 172), any event occurs as a result of which the Final Prospectus as then
supplemented or the Final Canadian MJDS Supplement as then supplemented would include any
untrue statement of a material fact or omit to state any material fact necessary to make
the statements therein in the light of the circumstances under which they were made at such
time not misleading, or if it shall be necessary to amend the Registration Statement or the
Canadian MJDS Base Prospectus, file a new registration statement or supplement the Final
Prospectus or the Final Canadian MJDS Supplement to comply with the Act or the Exchange Act
or the respective rules thereunder or NI 71-101, as the case may be, including in
connection with the use or delivery of the Final Prospectus and the Final Canadian MJDS
Supplement, the Company
15
promptly will (1) notify the Representatives of any such event, (2) prepare and file
with the Commission, subject to the first sentence of paragraph (i) of this Section 5, an
amendment or supplement or new registration statement which will correct such statement or
omission or effect such compliance, (3) use its best efforts to have any amendment to the
Registration Statement or new registration statement declared effective as soon as
practicable in order to avoid any disruption in use of the Final Prospectus and the Final
Canadian MJDS Supplement and (4) supply any supplemented Final Prospectus and any
supplemented Final Canadian MJDS Supplement to you in such quantities as you may reasonably
request.
(iv) As soon as practicable, the Company will make generally available to its security
holders and to the Representatives an earnings statement or statements of the Company and
its subsidiaries which will satisfy the provisions of Section 11(a) of the Act and Rule
158.
(v) The Company will use the net proceeds received by it from the sale of the
Securities pursuant to this Agreement in the manner specified in the Disclosure Package,
the Final Prospectus and the Final Canadian MJDS Supplement under the caption “Use of
Proceeds.”
(vi) The Company will use its best efforts to list the Securities on the NASDAQ Global
Select Market and the Toronto Stock Exchange and maintain its status as a “reporting
issuer” under the applicable securities laws of the Canadian Jurisdictions.
(vii) The Company will furnish to the Representatives and counsel for the Underwriters
signed copies of the Registration Statement (including exhibits thereto) and to each other
Underwriter a copy of the Registration Statement (without exhibits thereto) and signed
copies of the Canadian MJDS Base Prospectus and, so long as delivery of a prospectus by an
Underwriter or dealer may be required by the Act (including in such circumstances where
such requirement may be satisfied pursuant to Rule 172) or the MJDS Rule, as many copies of
each Preliminary Prospectus, the Preliminary Canadian MJDS Supplement, the Final
Prospectus, the Final Canadian MJDS Supplement, each Issuer Free Writing Prospectus and any
supplement thereto as the Representatives may reasonably request.
(viii) The Company will arrange, if necessary, for the qualification of the Securities
for sale under the laws of such jurisdictions as the Representatives may designate and will
maintain such qualifications in effect so long as required for the distribution of the
Securities; provided that in no event shall the Company be obligated to qualify to
do business in any jurisdiction where it is not now so qualified or to take any action that
would subject it to service of process in suits, other than those arising out of the
offering or sale of the Securities, in any jurisdiction where it is not now so subject.
16
(ix) The Company will not, without the prior written consent of the Representatives,
offer, sell, contract to sell, pledge, or otherwise dispose of (or enter into any
transaction which is designed to, or might reasonably be expected to, result in the
disposition (whether by actual disposition or effective economic disposition due to cash
settlement or otherwise) by the Company or any affiliate of the Company, directly or
indirectly, including the filing (or participation in the filing) of a registration
statement with the Commission in respect of, or establish or increase a put equivalent
position or liquidate or decrease a call equivalent position within the meaning of Section
16 of the Exchange Act, with respect to any other shares of Common Stock or any securities
convertible into, or exercisable or exchangeable for, such Common Stock, or publicly
announce an intention to effect any such transaction, for a period of 90 days after the
date of this Agreement, except that the Company may (1) file a registration statement with
the Commission in respect of the Securities and sell the Securities to the Underwriters
pursuant to this Agreement, (2) issue and sell Common Stock or grant performance shares,
stock appreciation rights, options or other equity-based awards pursuant to any employee
stock option plan, stock ownership plan or dividend reinvestment plan of the Company in
effect at the Execution Time, (3) issue Common Stock issuable upon the conversion of
securities or the exercise of warrants or options outstanding at the Execution Time, (4)
enter into a contract to sell, file a registration statement with respect to and issue as
consideration in connection with an acquisition of royalty interests or any corporation,
the primary business of which is acquiring and/or holding royalty interests, a number of
shares of Common Stock not in excess of 10% of the Company’s Common Stock issued and
outstanding immediately following the Closing Date; provided that the recipient of
such shares agrees in writing to be bound by the restrictions of this Section 5(ix) to the
same extent as the Company, (5) file with the Commission a prospectus supplement to the
Company’s Base Prospectus, a prospectus under the MJDS Rule or a registration statement as
required pursuant to that certain Registration Rights Agreement to be entered into between
the Company and CDA pursuant to the Master Agreement; provided that the Company
will not use, and, pursuant to that certain Stockholder Agreement, dated April 3, 2009, by
and among the Company, CDA and Teck Cominco Limited, a company organized under the laws of
British Columbia, Canada, and to the extent set forth therein, CDA will not be permitted to
use, such prospectus supplement in connection with any sales of Common Stock during the
Lock-Up Period as defined in the form of Lock-Up Agreement in Exhibit A hereto, and (6)
register the issuance of the applicable number of shares of Common Stock as required by and
in connection with the closing under the Master Agreement.
(x) The Company will comply with all applicable securities and other applicable laws,
rules and regulations, including, without limitation, the Sarbanes Oxley Act, and will use
its best efforts to cause the Company’s directors and officers, in their capacities as
such, to comply with such laws, rules and regulations, including, without limitation, the
provisions of the Sarbanes Oxley Act.
17
(xi) The Company will not take, directly or indirectly, any action designed to or that
would constitute or that might reasonably be expected to cause or result in, under the
Exchange Act or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Securities.
(xii) The Company agrees to pay the costs and expenses relating to the following
matters: (1) the preparation, printing or reproduction and filing with the Commission or
the Canadian Regulators, as the case may be, of (a) each Preliminary Prospectus, the Final
Prospectus and each Issuer Free Writing Prospectus, and each amendment and supplement to
any of the foregoing or the Registration Statement, and (b) each Canadian MJDS Base
Prospectus, the Preliminary Canadian MJDS Supplement, the Final Canadian MJDS Supplement
and each amendment and supplement to any of the foregoing; (2) the printing (or
reproduction) and delivery (including postage, air freight charges and charges for counting
and packaging) of such copies of the Registration Statement, each Preliminary Prospectus,
the Final Prospectus, each Issuer Free Writing Prospectus, each Canadian MJDS Base
Prospectus, the Preliminary Canadian MJDS Supplement, the Canadian Final Supplement and all
amendments or supplements to any of them, as may, in each case, be reasonably requested for
use in connection with the offering and sale of the Securities; (3) the preparation,
printing, authentication, issuance and delivery of certificates (if any) for the
Securities, including any stamp or transfer taxes in connection with the original issuance
and sale of the Securities; (4) the printing (or reproduction) and delivery of this
Agreement, any blue sky memorandum and all other agreements or documents printed (or
reproduced) and delivered in connection with the offering of the Securities; (5) the
registration of the Securities under the Exchange Act and the listing of the Securities on
the Toronto Stock Exchange and the NASDAQ Global Select Market; (6) any registration or
qualification of the Securities for offer and sale under the securities or blue sky laws of
the several states (including filing fees and the reasonable fees and expenses of counsel
for the Underwriters relating to such registration and qualification); (7) any filings
required to be made with the Financial Industry Regulatory Authority and/or the Canadian
Regulators (including filing fees and the reasonable fees and expenses of counsel for the
Underwriters relating to such filings); (8) the transportation and other expenses incurred
by or on behalf of Company representatives in connection with presentations to prospective
purchasers of the Securities; (9) the fees and expenses of the Company’s accountants and
the fees and expenses of counsel for the Company; and (10) all other costs and expenses
incident to the performance by the Company of its obligations under this Agreement.
(xiii) The Company agrees that, unless it has or shall have obtained the prior written
consent of the Representatives, and each Underwriter, severally and not jointly, agrees
with the Company that, unless it has or shall have obtained the prior written consent of
the Company, it has not made and will not make an offer relating to the Securities that
would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a
“free writing prospectus” (as defined in Rule
18
405) required to be filed by the Company with the Commission or retained by the
Company under Rule 433; provided that the prior written consent of the parties
hereto shall be deemed to have been given in respect of the free writing prospectuses
included in Schedule II hereto and any electronic roadshow that is a written communication.
Any such free writing prospectus consented to by the Representatives or the Company is
hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company agrees that
(1) it has treated and will treat, as the case may be, each Permitted Free Writing
Prospectus as an Issuer Free Writing Prospectus and (2) it has complied and will comply, as
the case may be, with the requirements of Rules 164 and 433 applicable to any Permitted
Free Writing Prospectus, including in respect of timely filing with the Commission,
legending and record keeping.
6. Conditions to the Obligations of the Underwriters. The obligations of the
Underwriters to purchase the Underwritten Securities and the Option Securities, as the case may be,
shall be subject to the accuracy of the representations and warranties on the part of the Company
contained herein as of the Execution Time, the Closing Date and any settlement date pursuant to
Section 3 hereof, to the accuracy of the statements of the Company made in any certificates
pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder
and to the following additional conditions:
(a) The Final Prospectus and the Final Canadian MJDS Supplement and any supplement thereto
have been filed with the Commission or the Canadian Regulators, as the case may be, in the manner
and within the time period required by Rule 424(b) or the MJDS Rule, as the case may be; any other
material required to be filed by the Company pursuant to Rule 433(d) shall have been filed with the
Commission within the applicable time periods prescribed for such filings by Rule 433; any
materials required to be filed by the Company pursuant to the MJDS Rule shall have been filed by
the Company with the Canadian Regulators within the applicable time periods; and no stop order
suspending the effectiveness of the Registration Statement or the Canadian MJDS Base Prospectus or
any notice objecting to its use shall have been issued and no proceedings for that purpose shall
have been instituted or threatened.
(b) The Company shall have requested and caused Xxxxx & Xxxxxxx L.L.P., U.S. counsel for the
Company, and Xxxxxxx Xxxxx & Xxxxxxxxx LLP, Canadian counsel for the Company, to have furnished to
the Representatives their opinions substantially in the forms set forth in Exhibits E-1 and E-2
hereto, respectively, dated the Closing Date and any settlement date and addressed to the
Representatives. In the case of the opinion to be provided by Xxxxxxx Xxxxx & Xxxxxxxxx LLP, they
may rely on the opinions of local counsel acceptable to the Representatives, acting reasonably, as
to the qualification of the Securities for sale to the public and as to other matters governed by
the laws of jurisdictions in Canada other than the provinces in which they are qualified to
practice.
(c) The Representatives shall have received from Xxxxxx Xxxxxxxx Xxxxx & Xxxxxxxx LLP, U.S.
counsel for the Underwriters, dated the Closing Date and any settlement date and addressed to the
Representatives, with respect to the issuance and sale of the Securities, the Registration
Statement, the Disclosure Package, the Final Prospectus (together with any supplement thereto) and
other related matters as the
19
Representatives may reasonably require, and the Company shall have furnished to such counsel
such documents as they request for the purpose of enabling them to pass upon such matters.
(d) The Company shall have furnished to the Representatives a certificate of the Company,
signed by the Chairman of the Board or the President and the principal financial or accounting
officer of the Company, dated the Closing Date and any settlement date, to the effect that the
signers of such certificate have carefully examined the Registration Statement, the Disclosure
Package, the Final Prospectus and any supplements or amendments thereto, as well as each electronic
roadshow that is a written communication used in connection with the offering of the Securities,
and this Agreement and that:
(i) the representations and warranties of the Company in this Agreement are true and
correct on and as of the Closing Date and any settlement date with the same effect as if
made on the Closing Date and any settlement date and the Company has complied with all the
agreements and satisfied all the conditions on its part to be performed or satisfied at or
prior to the Closing Date and any settlement date;
(ii) no stop order suspending the effectiveness of the Registration Statement or any
notice objecting to its use has been issued and no proceedings for that purpose have been
instituted or, to the Company’s knowledge, threatened; and
(iii) since the date of the most recent financial statements included or incorporated
by reference in the Disclosure Package and the Final Prospectus (exclusive of any
supplement thereto), there has been no Material Adverse Effect.
(e) The Company shall have requested and caused PricewaterhouseCoopers LLP to have furnished
to the Representatives, at the Execution Time and at the Closing Date and any settlement date,
letters (which may refer to letters previously delivered to the Representatives), dated
respectively as of the Execution Time and as of the Closing Date and any settlement date, in form
and substance satisfactory to the Representatives, confirming that it is an independent registered
public accounting firm within the meaning of the Act and the Exchange Act and the respective
applicable rules and regulations adopted by the Commission thereunder and stating to the effect
that:
(i) in its opinion the audited financial statements and financial statement schedules
included or incorporated by reference in the Registration Statement, the Preliminary
Prospectus and the Final Prospectus and reported on by them comply as to form in all
material respects with the applicable accounting requirements of the Act and the Exchange
Act and the related rules and regulations adopted by the Commission;
(ii) on the basis of (a) a reading of the latest unaudited financial statements made
available by the Company and its subsidiaries, (b) their limited review, in accordance with
standards established under Statement on Auditing
20
Standards No. 100, of the unaudited interim financial information for the six-month
period ended December 31, 2008, and as at December 31, 2008, (c) carrying out certain
specified procedures (but not an examination in accordance with generally accepted auditing
standards) which would not necessarily reveal matters of significance with respect to the
comments set forth in such letter, (d) a reading of the minutes of the meetings of the
shareholders, the directors, the audit committee and the compensation, nomination and
corporate governance committee of the Company, and (e) inquiries of certain officials of
the Company who have responsibility for financial and accounting matters of the Company and
its subsidiaries as to transactions and events subsequent to June 30, 2008, nothing came to
their attention which caused them to believe that:
(1) any unaudited financial statements included or incorporated by reference
in the Registration Statement, the Preliminary Prospectus and the Final Prospectus
do not comply as to form in all material respects with applicable accounting
requirements of the Act and with the related rules and regulations adopted by the
Commission with respect to financial statements included or incorporated by
reference in quarterly reports on Form 10-Q under the Exchange Act, and said
unaudited financial statements are not in conformity with generally accepted
accounting principles applied on a basis substantially consistent with that of the
audited financial statements included or incorporated by reference in the
Registration Statement, the Preliminary Prospectus and the Final Prospectus;
(2) with respect to the period subsequent to December 31, 2008, there were, at
a specified date not more than five days prior to the date of the letter, any
change, increase or decrease in capital stock or decrease in long-term debt of the
Company and its subsidiaries as compared with the amounts shown on the December 31,
2008 consolidated balance sheet included or incorporated by reference in the
Registration Statement, the Preliminary Prospectus and the Final Prospectus, except
in all instances for changes or decreases set forth in such letter, in which case
the letter shall be accompanied by an explanation by the Company as to the
significance thereof unless said explanation is not deemed to be necessary by the
Representatives;
(3) the information included or incorporated by reference in the Registration
Statement, the Preliminary Prospectus, the Final Prospectus in response to
Regulation S-K, Item 301 (Selected Financial Data), is not in conformity with the
applicable disclosure requirements of Regulation S-K; and
they have performed certain other specified procedures as a result of which they determined that
certain information of an accounting, financial or statistical nature (which is limited to
accounting, financial or statistical information derived from the general accounting records of the
Company and its subsidiaries) set forth in the Registration Statement, the Preliminary Prospectus,
the Final Prospectus and in Exhibit 12.1 of the
21
Registration Statement, including the information set forth under the captions “Prospectus
Supplement Summary,” “Risk Factors,” “Recent Developments,” “Dividend History” and “Capitalization”
in the Preliminary Prospectus and the Final Prospectus, the information set forth under the
captions “The Company,” “Ratio of Earnings to Fixed Charges and Preferred Stock Dividends,” and
“Description of Common Stock” in the Prospectus, the information the Company’s Definitive Proxy
Statement, incorporated by reference in the Registration Statement, the Preliminary Prospectus and
the Final Prospectus, the information in Items 1, 1A, 2, 5, 6, 7, 7A and 11 of the Company’s Annual
Report on Form 10-K, incorporated by reference in the Registration Statement, the Preliminary
Prospectus and the Final Prospectus, the information in Items 1A, 2 and 3 of the Company’s
Quarterly Reports on Form 10-Q, incorporated by reference in the Registration Statement, the
Preliminary Prospectus and the Final Prospectus and the information in Items 1.01, 8.01 and 9.01 of
the information in the Company’s Current Reports on Form 8-K, incorporated by reference in the
Registration Statement, the Preliminary Prospectus and the Final Prospectus, agrees with the
accounting records of the Company and its subsidiaries, excluding any questions of legal
interpretation.
References to the Final Prospectus in this paragraph (e) include any supplement thereto at the
date of the letter.
(f) Subsequent to the Execution Time or, if earlier, the dates as of which information is
given in the Registration Statement (exclusive of any amendment thereof) and the Final Prospectus
(exclusive of any amendment or supplement thereto), there shall not have been (1) any change or
decrease specified in the letter or letters referred to in paragraph (e) of this Section 6 or
(2) any Material Adverse Effect, the effect of which, in any case referred to in clause (1) or (2)
above, is, in the sole judgment of the Representatives, so material and adverse as to make it
impractical or inadvisable to proceed with the offering or delivery of the Securities as
contemplated by the Registration Statement (exclusive of any amendment thereof), the Disclosure
Package and the Final Prospectus (exclusive of any amendment or supplement thereto).
(g) Prior to the Closing Date and any settlement date, the Company shall have furnished to the
Representatives such further information, certificates and documents as the Representatives may
reasonably request.
(h) The Securities shall have been approved for listing on the NASDAQ Global Select Market
and, prior to the Closing Date, the Securities shall have been conditionally approved for listing,
subject to the satisfaction of the customary conditions, on the Toronto Stock Exchange, subject
only to official notice of issuance, and satisfactory evidence of such actions shall have been
provided to the Representatives.
(i) At the Execution Time, the Company shall have furnished to the Representatives (1) a
letter substantially in the form of Exhibit A to this Agreement from each officer and director of
the Company, and (2) a letter substantially in the form of Exhibit B to this Agreement from CDA.
(j) The Company shall have requested and caused counsel qualified in the Province of British
Colombia to have furnished to the Representatives its opinion, dated
22
the Closing Date and any settlement date and addressed to the Representatives, substantially
to the effect that RGLD Gold Canada, Inc. is a corporation incorporated and existing under the laws
of the Province of British Columbia and has the corporate power and capacity to own, lease or
operate its properties and assets, and to carry on its business as described in the Disclosure
Package and the Final Prospectus.
If any of the conditions specified in this Section 6 shall not have been fulfilled when and as
provided in this Agreement, or if any of the opinions and certificates mentioned above or elsewhere
in this Agreement shall not be reasonably satisfactory in form and substance to the Representatives
and counsel for the Underwriters, this Agreement and all obligations of the Underwriters hereunder
may be canceled at, or at any time prior to, the Closing Date by the Representatives. Notice of
such cancellation shall be given to the Company in writing or by telephone or facsimile confirmed
in writing.
The documents required to be delivered by this Section 6 shall be delivered at the office of
Xxxxxx Xxxxxxxx Xxxxx & Xxxxxxxx LLP, counsel for the Underwriters, at Xxx Xxxxxxx Xxxxx, Xxx Xxxx,
Xxx Xxxx 00000, on the Closing Date.
7. Reimbursement of Underwriters’ Expenses. If the sale of the Securities provided
for herein is not consummated because any condition to the obligations of the Underwriters set
forth in Section 6 hereof is not satisfied, because of any termination pursuant to Section 10
hereof or because of any refusal, inability or failure on the part of the Company to perform any
agreement herein or comply with any provision hereof other than by reason of a default by any of
the Underwriters, the Company will reimburse the Underwriters severally through the Representatives
on demand for all out-of-pocket expenses (including reasonable fees and disbursements of counsel)
that shall have been incurred by them in connection with the proposed purchase and sale of the
Securities.
8. Indemnification and Contribution. (a) The Company agrees to indemnify and hold
harmless each Underwriter, the directors, officers, employees and agents of each Underwriter and
each person who controls any Underwriter within the meaning of either the Act or the Exchange Act
against any and all losses, claims, damages or liabilities, joint or several, to which they or any
of them may become subject under the Act, the Exchange Act or other federal or state statutory law
or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities
(or actions in respect thereof) arise out of or are based upon any untrue statement or alleged
untrue statement of a material fact contained in the registration statement for the registration of
the Securities as originally filed or in any amendment thereof, or in the Base Prospectus, any
Preliminary Prospectus or any other preliminary prospectus supplement relating to the Securities,
the Final Prospectus or any Issuer Free Writing Prospectus, or in any amendment thereof or
supplement thereto, or arise out of or are based upon the omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein
not misleading, and agrees to reimburse each such indemnified party, as incurred, for any legal or
other expenses reasonably incurred by them in connection with investigating or defending any such
loss, claim, damage, liability or action; provided, however, that the Company will
not be liable in any such case to the extent that any such loss, claim, damage or liability arises
out of or is based upon any such untrue statement or alleged untrue statement or omission or
alleged
23
omission made therein in reliance upon and in conformity with written information furnished to
the Company by or on behalf of any Underwriter through the Representatives specifically for
inclusion therein. This indemnity agreement will be in addition to any liability that the Company
may otherwise have.
(b) Each Underwriter severally and not jointly agrees to indemnify and hold harmless the
Company, each of its directors, each of its officers who signs the Registration Statement, and each
person who controls the Company within the meaning of either the Act or the Exchange Act to the
same extent as the foregoing indemnity from the Company to each Underwriter, but only with
reference to written information relating to such Underwriter furnished to the Company by or on
behalf of such Underwriter through the Representatives specifically for inclusion in the documents
referred to in the foregoing indemnity, it being understood and agreed that the only such
information furnished by or on behalf of any Underwriter consists of the information described as
such in the letter agreement between you and the Representatives dated the date hereof. This
indemnity agreement will be in addition to any liability that any Underwriter may otherwise have.
(c) Promptly after receipt by an indemnified party under this Section 8 of notice of the
commencement of any action, such indemnified party will, if a claim in respect thereof is to be
made against the indemnifying party under this Section 8, notify the indemnifying party in writing
of the commencement thereof, but the failure so to notify the indemnifying party (i) will not
relieve it from liability under paragraph (a) or (b) above unless and to the extent it did not
otherwise learn of such action and such failure results in the forfeiture by the indemnifying party
of substantial rights and defenses and (ii) will not, in any event, relieve the indemnifying party
from any obligations to any indemnified party other than the indemnification obligation provided in
paragraph (a) or (b) above. The indemnifying party shall be entitled to appoint counsel of the
indemnifying party’s choice at the indemnifying party’s expense to represent the indemnified party
in any action for which indemnification is sought (in which case the indemnifying party shall not
thereafter be responsible for the fees and expenses of any separate counsel retained by the
indemnified party or parties except as set forth below); provided, however, that
such counsel shall be satisfactory to the indemnified party. Notwithstanding the indemnifying
party’s election to appoint counsel to represent the indemnified party in an action, the
indemnified party shall have the right to employ separate counsel (including local counsel), and
the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel
if (i) the use of counsel chosen by the indemnifying party to represent the indemnified party would
present such counsel with a conflict of interest, (ii) the actual or potential defendants in, or
targets of, any such action include both the indemnified party and the indemnifying party and the
indemnified party shall have reasonably concluded that there may be legal defenses available to it
and/or other indemnified parties which are different from or additional to those available to the
indemnifying party, (iii) the indemnifying party shall not have employed counsel satisfactory to
the indemnified party to represent the indemnified party within a reasonable time after notice of
the institution of such action or (iv) the indemnifying party shall authorize the indemnified party
to employ separate counsel at the expense of the indemnifying party. An indemnifying party will
not, without the prior
24
written consent of the indemnified parties, settle or compromise or consent to the entry of
any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect
of which indemnification or contribution may be sought hereunder (whether or not the indemnified
parties are actual or potential parties to such claim or action) unless such settlement, compromise
or consent (A) includes an unconditional release of each indemnified party from all liability
arising out of such claim, action, suit or proceeding, and (B) does not include a statement as to,
or an admission of, fault, culpability or a failure to act by, or on behalf of, any indemnified
party.
(d) In the event that the indemnity provided in paragraph (a) or (b) of this Section 8 is
unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company
and the Underwriters severally agree to contribute to the aggregate losses, claims, damages and
liabilities (including legal or other expenses reasonably incurred in connection with investigating
or defending the same) (collectively “Losses”) to which the Company and one or more of the
Underwriters may be subject in such proportion as is appropriate to reflect the relative benefits
received by the Company and by the Underwriters from the offering of the Securities;
provided, however, that in no case shall any Underwriter (except as may be provided
in any agreement among underwriters relating to the offering of the Securities) be responsible for
any amount in excess of the underwriting discount or commission applicable to the Securities
purchased by such Underwriter hereunder. If the allocation provided by the immediately preceding
sentence is unavailable for any reason, the Company and the Underwriters severally shall contribute
in such proportion as is appropriate to reflect not only such relative benefits but also the
relative fault of the Company and of the Underwriters in connection with the statements or
omissions which resulted in such Losses, as well as any other relevant equitable considerations.
Benefits received by the Company shall be deemed to be equal to the total net proceeds from the
offering (before deducting expenses) received by it, and benefits received by the Underwriters
shall be deemed to be equal to the total underwriting discounts and commissions, in each case as
set forth on the cover page of the Final Prospectus. Relative fault shall be determined by
reference to, among other things, whether any untrue or any alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information provided
by the Company on the one hand or the Underwriters on the other, the intent of the parties and
their relative knowledge, access to information and opportunity to correct or prevent such untrue
statement or omission. The Company and the Underwriters agree that it would not be just and
equitable if contribution were determined by pro rata allocation or any other method of allocation
which does not take account of the equitable considerations referred to above. Notwithstanding the
provisions of this paragraph (d), no person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. For purposes of this Section 8, each person who
controls an Underwriter within the meaning of either the Act or the Exchange Act and each director,
officer, employee and agent of an Underwriter shall have the same rights to contribution as such
Underwriter, and each person who controls the Company within the meaning of either the Act or the
Exchange Act, each officer of the Company who shall have signed the Registration Statement and each
director of the Company shall have the
25
same rights to contribution as the Company, subject in each case to the applicable terms and
conditions of this paragraph (d).
9. Default by an Underwriter. If any one or more Underwriters shall fail to purchase
and pay for any of the Securities agreed to be purchased by such Underwriter or Underwriters
hereunder and such failure to purchase shall constitute a default in the performance of its or
their obligations under this Agreement, the remaining Underwriters shall be obligated severally to
take up and pay for (in the respective proportions which the amount of Securities set forth
opposite their names in Schedule I to this Agreement bears to the aggregate amount of Securities
set forth opposite the names of all the remaining Underwriters) the Securities which the defaulting
Underwriter or Underwriters agreed but failed to purchase; provided, however, that
in the event that the aggregate amount of Securities which the defaulting Underwriter or
Underwriters agreed but failed to purchase shall exceed 10% of the aggregate amount of Securities
set forth in Schedule I to this Agreement, the remaining Underwriters shall have the right to
purchase all, but shall not be under any obligation to purchase any, of the Securities, and if such
non-defaulting Underwriters do not purchase all the Securities, this Agreement will terminate
without liability to any non-defaulting Underwriter or the Company. In the event of a default by
any Underwriter as set forth in this Section 9, the Closing Date and any settlement date shall be
postponed for such period, not exceeding five Business Days, as the Representatives shall determine
in order that the required changes in the Registration Statement and the Final Prospectus or in any
other documents or arrangements may be effected. Nothing contained in this Agreement shall relieve
any defaulting Underwriter of its liability, if any, to the Company and any non-defaulting
Underwriter for damages occasioned by its default hereunder.
10. Termination. This Agreement shall be subject to termination in the absolute
discretion of the Representatives, by notice given to the Company prior to delivery of and payment
for the Securities, if at any time prior to such time (1) trading in the Company’s Common Stock
shall have been suspended by the Commission, the Toronto Stock Exchange or the NASDAQ Global Select
Market or trading in securities generally on the New York Stock Exchange or the NASDAQ Global
Select Market shall have been suspended or limited or minimum prices shall have been established on
such Exchange or the NASDAQ Global Select Market, (2) a banking moratorium shall have been declared
by Federal, New York State or Canadian authorities or (3) there shall have occurred any outbreak or
escalation of hostilities, declaration by the United States or Canada of a national emergency or
war, major terrorist attack in a world commercial or financial center, or other calamity or crisis
the effect of which on financial markets is such as to make it, in the sole judgment of the
Representatives, impractical or inadvisable to proceed with the offering or delivery of the
Securities as contemplated by any Preliminary Prospectus or the Final Prospectus (exclusive of any
amendment or supplement thereto).
11. Representations and Indemnities to Survive. The respective agreements,
representations, warranties, indemnities and other statements of the Company or its officers and of
the Underwriters set forth in or made pursuant to this Agreement will remain in full force and
effect, regardless of any investigation made by or on behalf of
26
any Underwriter or the Company or any of the officers, directors, employees, agents or
controlling persons referred to in Section 8 hereof, and will survive delivery of and payment for
the Securities. The provisions of Sections 7 and 8 hereof shall survive the termination or
cancellation of this Agreement.
12. Notices. All communications hereunder will be in writing and effective only on
receipt, and, if sent to the Representatives, will be mailed, delivered or telefaxed to (a) HSBC
Securities (USA) Inc., 000 Xxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000, attention: Xxxx Xxxxxxxxxx (fax
no.: (000) 000-0000), (b) Xxxxxxx, Xxxxx & Co., 00 Xxxxx Xxxxxx, 00xx Xxxxx, Xxx Xxxx,
Xxx Xxxx 00000, attention: Registration Department (fax no.: (000) 000-0000), and (c) Scotia
Capital (USA) Inc., Xxx Xxxxxxx Xxxxx, Xxx Xxxx, Xxx Xxxx 00000, attention: Xxxxx Xxxxxx (fax no.:
(000) 000-0000), with a copy to Xxxxxx Xxxxxxxx Xxxxx & Xxxxxxxx LLP, Xxx Xxxxxxx Xxxxx, Xxx Xxxx,
Xxx Xxxx 00000, attention: Xxxxx X. Xxxxxxxx (fax no.: (000) 000-0000); or, if sent to the
Company, will be mailed, delivered or telefaxed to Royal Gold, Inc., 0000 Xxxxxxx Xxxxxx, Xxxxx
0000, Xxxxxx, Xxxxxxxx 00000, attention: Xxxx Xxxxxx, President and Chief Executive Officer (fax
no.: (000) 000-0000), with a copy to Xxxxx & Xxxxxxx, L.L.P., 0000 Xxxxxxxxxxx Xxxxxx, Xxxxx 0000,
Xxxxxx, Xxxxxxxx 00000, attention: Xxxx Xxxxxx (fax no.: (000) 000-0000).
13. Successors. This Agreement will inure to the benefit of and be binding upon the
parties to this Agreement and their respective successors and the officers, directors, employees,
agents and controlling persons referred to in Section 8 hereof, and no other person will have any
right or obligation hereunder.
14. Applicable Law. This Agreement will be governed by and construed in accordance
with the laws of the State of New York applicable to contracts made and to be performed within the
State of New York.
15. Counterparts. This Agreement may be signed in one or more counterparts, each of
which shall constitute an original and all of which together shall constitute one and the same
agreement.
16. Headings. The section headings used herein are for convenience only and shall not
affect the construction hereof.
17. Definitions. The terms that follow, when used in this Agreement, shall have the
meanings indicated.
“Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations of the
Commission promulgated thereunder.
“Applicable
Time” shall mean 10:30 PM (New York City time) on April 7, 2009.
“Base Prospectus” shall mean the base prospectus referred to in Section 1(i) hereof contained
in the Registration Statement at the Effective Date.
27
“Business Day” shall mean any day other than a Saturday, a Sunday or a legal holiday or a day
on which banking institutions or trust companies are authorized or obligated by law to close in New
York City.
“Commission” shall mean the Securities and Exchange Commission.
“Disclosure Package” shall mean (i) the Preliminary Prospectus or Preliminary Canadian MJDS
Supplement used most recently prior to the Applicable Time, (ii) the Issuer Free Writing
Prospectuses, if any, identified in Schedule II hereto, and (iii) any other Free Writing Prospectus
that the parties hereto shall hereafter expressly agree in writing to treat as part of the
Disclosure Package.
“Effective Date” shall mean each date and time that the Registration Statement, any
post-effective amendment or amendments thereto became or becomes effective.
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission promulgated thereunder.
“Execution Time” shall mean the date and time that this Agreement is executed and delivered by
the parties to this Agreement.
“Final Canadian MJDS Supplement” shall mean the prospectus supplement relating to the
Securities that was first filed pursuant to the MJDS Rule after the Execution Time, together with
the Canadian MJDS Base Prospectus.
“Final Prospectus” shall mean the prospectus supplement relating to the Securities that was
first filed pursuant to Rule 424(b) after the Execution Time, together with the Base Prospectus.
“Free Writing Prospectus” shall mean a free writing prospectus, as defined in Rule 405.
“Issuer Free Writing Prospectus” shall mean an issuer free writing prospectus, as defined in
Rule 433.
“Material Adverse Effect” shall mean any event that (i) could reasonably be expected to have a
material adverse effect on the performance of this Agreement or the consummation of any of the
transactions contemplated hereby or (ii) could reasonably be expected to have a material adverse
effect on the condition (financial or otherwise), prospects, earnings, business or properties of
the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the
ordinary course of business.
“Preliminary Canadian MJDS Supplement” shall mean any preliminary prospectus supplement to the
Canadian MJDS Base Prospectus referred to in the preamble of this Agreement, which is used prior to
the filing of the Final Canadian MJDS Supplement, together with the Canadian MJDS Base Prospectus.
28
“Preliminary Prospectus” shall mean any preliminary prospectus supplement to the Base
Prospectus referred to in Section 1(i) hereof, which is used prior to the filing of the Final
Prospectus, together with the Base Prospectus.
“Registration Statement” shall mean the registration statement referred to in Section 1(i)
hereof including exhibits and financial statements and any prospectus supplement relating to the
Securities that is filed with the Commission pursuant to Rule 424(b) and deemed part of such
registration statement pursuant to Rule 430B, as amended on each Effective Date and, in the event
any post-effective amendment thereto becomes effective prior to the Closing Date, shall also mean
such registration statement as so amended.
“Rule 158”, “Rule 163”, “Rule 164”, “Rule 172”, “Rule 405”, “Rule 415”, “Rule 424”, “Rule
430B”, “Rule 433”, “Rule 456” and “Rule 457” refer to such rules under the Act.
“Significant Subsidiary” shall mean each significant subsidiary of the Company as defined by
Rule 1-02 of Regulation S-X or listed on Exhibit C attached hereto.
18. Arm’s Length Transaction. The Company acknowledges and agrees that the
Underwriters are acting solely in the capacity of an arm’s length contractual counterparty to the
Company with respect to the offering of Securities contemplated hereby (including in connection
with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an
agent of, the Company or any other person. Additionally, neither the Representatives nor any other
Underwriter is advising the Company or any other person as to any legal, tax, investment,
accounting or regulatory matters in any jurisdiction. The Company shall consult with its own
advisors concerning such matters and shall be responsible for making its own independent
investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall
have no responsibility or liability to the Company with respect thereto. Any review by the
Underwriters of the Company, the transactions contemplated hereby or other matters relating to such
transactions will be performed solely for the benefit of the Underwriters and shall not be on
behalf of the Company.
This Agreement supersedes all prior agreements and understandings (whether written or oral)
between the Company and the Underwriters, or any of them, with respect to the subject matter
hereof.
29
If the foregoing is in accordance with your understanding of our agreement, please sign and
return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall
represent a binding agreement between the Company and the several Underwriters.
Very truly yours, ROYAL GOLD, INC. |
||||
By: | ||||
Name: | ||||
Title: | ||||
The foregoing Agreement is hereby confirmed and accepted as of the date first above written.
HSBC SECURITIES (USA) INC. | ||||
By: |
||||
XXXXXXX, XXXXX & CO. | ||||
By: |
||||
SCOTIA CAPITAL (USA) INC. | ||||
By: |
||||
For themselves and the other several Underwriters named in Schedule I to the foregoing Agreement.
Signature Page
SCHEDULE I
Number of Underwritten | ||||
Underwriters | Securities to be Purchased | |||
HSBC Securities (USA) Inc. |
1,950,000 | |||
Xxxxxxx, Xxxxx & Co. |
1,950,000 | |||
Scotia Capital (USA) Inc. |
1,300,000 | |||
Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx Incorporated |
650,000 | |||
NBF Securities (USA) Corp. |
650,000 | |||
Total |
6,500,000 | |||
SI-1
SCHEDULE II
SCHEDULE OF FREE WRITING PROSPECTUSES INCLUDED IN THE
DISCLOSURE PACKAGE
DISCLOSURE PACKAGE
None.
SII-1